DiscoverMarkets & Money Today | 2 Min News | The Daily News Now!Kyverna Therapeutics stock surges after positive myasthenia gravis trial data By Investing.com
Kyverna Therapeutics stock surges after positive myasthenia gravis trial data By Investing.com

Kyverna Therapeutics stock surges after positive myasthenia gravis trial data By Investing.com

Update: 2025-10-29
Share

Description

Kyverna Therapeutics' experimental treatment, KYV-101, shows promising results in Phase Two study for generalized myasthenia gravis (gMG). All patients hit key milestones in improving daily symptoms, with significant reductions in clinical scores after 24 weeks. The treatment was well-tolerated, with no severe side effects. Kyverna plans to start Phase Three trial by the end of the year, potentially setting a new standard for gMG treatment.

The Daily News Now! — Every city. Every story. AI-powered.


Hosted on Acast. See acast.com/privacy for more information.

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Kyverna Therapeutics stock surges after positive myasthenia gravis trial data By Investing.com

Kyverna Therapeutics stock surges after positive myasthenia gravis trial data By Investing.com